Prostate Cancer: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis - Product Image

Prostate Cancer: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis

  • ID: 3797462
  • Drug Pipelines
  • 354 pages
  • Datamonitor Healthcare
1 of 3
The value of the prostate cancer market will more than double during 2015-24, reaching $13.5bn in 2024 at a compound annual growth rate (CAGR) of 8.6%.

This report addresses the following questions:

- Which products will drive the growth of the prostate cancer market during 2015-24?
- Which geographic markets will experience the largest growth?
- Which pipeline therapies will have the largest impact on treatment practices in prostate cancer?
- What are the most valuable treatment settings within prostate cancer being targeted by drug developers?
- What is the commercial outlook for current market leaders Xtandi and Zytiga over the forecast period?
Note: Product cover images may vary from those shown
2 of 3
FORECAST: PROSTATE CANCER

- Executive Summary
- Market Overview and Trends
- Market Definition and Methodology
- DCVAC/PCa
- Galeteronem
- Jevtana (cabazitaxel)
- JNJ-560219
- Lupron (leuprolide)
- Masitinib
- ODM-2
- ProstAtak (AdV-tk + valacyclovir)
- PROSTVAC
- Provenge (sipuleucel-T)
- Taxotere (docetaxel)
- Xofigo (radium-223)
- Xtandi (enzalutamide)
- Zoladex (goserelin)
- Zytiga (abiraterone acetate)
- Primary Research Methodology

TREATMENT: PROSTATE CANCER

- Executive Summary
- Primary Research Methodology
- Disease Definition and Diagnosis
- Patient Segmentation
- Country Treatment Trees
- Current Treatment Options
- Prescribing Trends

EPIDEMIOLOGY: PROSTATE CANCER

- Executive Summary
- Sources and Methodology
- Forecast
- Epidemiologist Insight
- Strengths and Limitations

MARKETED DRUGS: PROSTATE CANCER

- Executive Summary
- Product Overview
- Product profile: Jevtana
- Product profile: Lupron
- Product profile: Provenge
- Product profile: Taxotere
- Product profile: Xofigo
- Product profile: Xtandi
- Product profile: Zytiga

PIPELINE: PROSTATE CANCER

- Executive Summary
- Clinical Pipeline Overview
- Target Product Profile
- Recently Discontinued Drugs
- Clinical Trial Design
- Product profile (late stage): DCVAC/PCa
- Product profile (late stage): JNJ-560219
- Product profile (late stage): ODM-2
- Product profile (late stage): PROSTVAC
- Product profile (late stage): ProstAtak
- Product profile (late stage): galeterone
- Product profile (late stage): masitinib
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll